4,663 results match your criteria Cancer immunology immunotherapy : CII[Journal]


Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy.

Cancer Immunol Immunother 2019 Apr 17. Epub 2019 Apr 17.

Department of Surgery, Division of Urology, Southern Illinois University School of Medicine, Springfield, IL, USA.

Objectives: Advanced age and female sex have been associated with worse outcomes in patients undergoing radical cystectomy for muscle-invasive bladder cancer. A reduced immune response has been implicated as a mechanism. The objective of our study was to analyze the expression patterns of various cellular proteins active in bladder cancer immune pathways, and assess the correlation between age, sex, and the expression of these immune markers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02340-w
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02340-wDOI Listing
April 2019
2 Reads

MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.

Cancer Immunol Immunother 2019 Apr 16. Epub 2019 Apr 16.

Department of Dermatology, University Clinic Essen, Essen, Germany.

Background: Merkel cell carcinoma (MCC) is an aggressive skin cancer in which PD-1/PD-L1 blockade has shown remarkable response rates. However, a significant proportion of patients shows primary or secondary resistance against PD-1/PD-L1 inhibition, with HLA class-I downregulation and insufficient influx of CD8 T cells into the tumor as possible immune escape mechanisms. Histone deacetylase inhibitors (HDACi) have been demonstrated to reverse low HLA class-I expression caused by epigenetic downregulation of the antigen machinery (APM) in vitro and in pre-clinical models in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02341-9DOI Listing
April 2019
1 Read

Cryptotanshinone has curative dual anti-proliferative and immunotherapeutic effects on mouse Lewis lung carcinoma.

Cancer Immunol Immunother 2019 Apr 10. Epub 2019 Apr 10.

Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick National Laboratory for Cancer Research (FNLCR), Rm 21-89/31-19, Bldg 560, 1050 Boyles Street, Frederick, MD, 21702-1201, USA.

Lung cancer is currently the leading cause of cancer-related mortality with very limited effective therapy. Screening of a variety of traditional Chinese medicines (TCMs) for their capacity to inhibit the proliferation of human lung cancer A549 cells and to induce the in vitro maturation of human DCs led to the identification of cryptotanshinone (CT), a compound purified from the TCM Salvia miltiorrhiza Bunge. Here, CT was shown to inhibit the proliferation of mouse Lewis lung carcinoma (LLC) cells by upregulating p53, downregulating cyclin B1 and Cdc2, and, consequently, inducing G2/M cell-cycle arrest of LLC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02326-8DOI Listing

Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy.

Cancer Immunol Immunother 2019 Apr 8. Epub 2019 Apr 8.

Department of Dermatology, University Hospital Cologne, Kerpener Strasse 62, 50937, Cologne, Germany.

Background: Pleomorphic dermal sarcomas (PDS) are sarcomas of the skin with local recurrences in up to 28% of cases, and distant metastases in up to 20%. Although recent evidence provides a strong rational to explore immunotherapeutics in solid tumors, nothing is known about the immune environment of PDS.

Methods: In the current study, a comprehensive immune-phenotyping of 14 PDS using RNA and protein expression analyses, as well as quantitative assessment of immune cells using an image-analysis tool was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02339-3DOI Listing

Sirtuin2 enhances the tumoricidal function of liver natural killer cells in a mouse hepatocellular carcinoma model.

Cancer Immunol Immunother 2019 Apr 6. Epub 2019 Apr 6.

Hubei Clinical Center and Key Laboratory for Intestinal and Colorectal Disease, Department of Gastroenterology, Zhongnan Hospital of Wuhan University, 169 East Lake Road, Wuchang District, Wuhan City, Hubei Province, China.

Hepatocellular carcinoma (HCC) is the third most lethal cancer in the world. Natural killer (NK) cell-mediated immunity is crucial for tumor surveillance and therapy. Characterization of the regulatory mechanisms of NK cell function is important for developing novel immunotherapies against HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02337-5DOI Listing
April 2019
1 Read

T-cell recognition of non-mutated tumor antigens in healthy individuals: connecting endogenous immunity and tumor dormancy.

Cancer Immunol Immunother 2019 May 6;68(5):705-707. Epub 2019 Apr 6.

Cancer Immunology and Immunotherapy Center, St Savas Cancer Hospital, 171 Alexandras Ave, 11522, Athens, Greece.

The concept of a dual functional programme of the immune system to destroy malignant cells but also to edit their immunogenic profile, considerably improved our understanding of the process of tumor evolution in the context of a continuum of interactions between tumor cells and immune lymphocytes. Such an endogenous antitumor immunity throughout the period of cancer development established the concept of cancer immunomodulation which is practically based on a process of selection of more clonal tumors which are manageable by the immune system and constitute the equilibrium phase of immunoediting. The duration of this phase is very important, because the immune system keeps the tumor in a dormant state via cell interactions which establish a balanced state of tumor immunosurveillance versus tumor immune evasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02335-7DOI Listing
May 2019
1 Read

Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.

Cancer Immunol Immunother 2019 Apr 5. Epub 2019 Apr 5.

Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein Zuid 32, 6525 GA, Nijmegen, The Netherlands.

Gliomas appear to be highly immunosuppressive tumors, with a strong myeloid component. This includes MDSCs, which are a heterogeneous, immature myeloid cell population expressing myeloid markers Siglec-3 (CD33) and CD11b and lacking markers of mature myeloid cells including MHC II. Siglec-3 is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family and has been suggested to promote MDSC expansion and suppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02332-wDOI Listing
April 2019
1 Read

Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.

Cancer Immunol Immunother 2019 May 5;68(5):861-870. Epub 2019 Apr 5.

Immunology Unit, University of Extremadura, Caceres, Spain.

The incidence of some types of tumours has increased progressively in recent years and is expected to continue growing in the coming years due in part to the aging of the population. The design of new therapies based on natural killer (NK) cells opens new possibilities especially for the treatment of elderly patients who are particularly susceptible to the toxicity of conventional chemotherapy treatments. In recent years, the potential use of NK cells in cancer immunotherapy has been of great interest thanks to advances in the study of NK cell biology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02336-6DOI Listing
May 2019
2 Reads

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.

Cancer Immunol Immunother 2019 Apr 5. Epub 2019 Apr 5.

Pathology Department, INSERM UMR_S1165, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris (APHP), 1 Avenue Claude Vellefaux, 75010, Paris, France.

Background: Adnexal carcinomas are rare and heterogeneous skin tumors, for which no standard treatments exist for locally advanced or metastatic tumors.

Aim Of The Study: To evaluate the expression of PD-L1 and CD8 in adnexal carcinomas, and to study the association between PD-L1 expression, intra-tumoral T cell CD8 infiltrate, and metastatic evolution.

Materials And Methods: Eighty-three adnexal carcinomas were included. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02334-8
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02334-8DOI Listing
April 2019
4 Reads

"Tumor Immunology Meets Oncology (TIMO) XIV", May 24-26th 2018, Halle/Saale, Germany.

Cancer Immunol Immunother 2019 Apr 4. Epub 2019 Apr 4.

Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Magdeburger Str. 02, 06112, Halle, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02329-5
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02329-5DOI Listing
April 2019
1 Read

Unlocking the therapeutic potential of primary tumor-draining lymph nodes.

Cancer Immunol Immunother 2019 Apr 3. Epub 2019 Apr 3.

Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Lymph nodes draining the primary tumor are essential for the initiation of an effective anti-tumor T-cell immune response. However, cancer-derived immune suppressive factors render the tumor-draining lymph nodes (TDLN) immune compromised, enabling tumors to invade and metastasize. Unraveling the different mechanisms underlying this immune escape will inform therapeutic intervention strategies to halt tumor spread in early clinical stages. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02330-yDOI Listing
April 2019
1 Read

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Cancer Immunol Immunother 2019 Mar 27. Epub 2019 Mar 27.

Departments of Medical Oncology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

In the original publication of the article the following abstract and keywords were inadvertently omitted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02328-6DOI Listing
March 2019
1 Read

The role of immune infiltrates as prognostic biomarkers in patients with breast cancer.

Cancer Immunol Immunother 2019 Mar 23. Epub 2019 Mar 23.

Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Ave., 115 22, Athens, Greece.

The presence of immune infiltrates in the tumor microenvironment has been documented in many types of cancer. Moreover, the preexistent or endogenous immunity which consists of interactions between intratumoral lymphocytes and tumor cells is mostly relevant for the successful application of various anticancer therapies, including standard chemotherapy, immune checkpoint inhibition-based immunotherapy and targeted therapies. The immunoscore defines densities of intratumoral immune infiltrates which determine poor or favorable prognosis depending on their quantity and quality in the tumor compartments. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02327-7
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02327-7DOI Listing
March 2019
5 Reads

MDSC and beyond: a symposium-in-writing on myeloid cells with immunoregulatory activity by members of the Mye-EUNITER network.

Authors:
Sven Brandau

Cancer Immunol Immunother 2019 Apr;68(4):531-532

Research Division, Department of Otorhinolaryngology, University Hospital Essen, Hufelandstrasse 55, 45122, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02325-9DOI Listing

An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma.

Cancer Immunol Immunother 2019 Mar 16. Epub 2019 Mar 16.

Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Background: Immune cells can regulate disease progression and response to treatment in multiple tumor types, but their activities in human soft tissue sarcoma are poorly characterized.

Methods: Marker-defined immune cell subsets were characterized from a tumor microenvironmental perspective in two independent cohorts of human soft tissue sarcoma by multiplex IHC, quantitative PCR and/or bioinformatics.

Results: B cell profiling revealed a prognostic role for CD20 protein (cohort 1, 33 patients) and MS4A1 gene expression (cohort 2, 265 patients). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02322-yDOI Listing

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Cancer Immunol Immunother 2019 Mar 15. Epub 2019 Mar 15.

Division of Population Sciences, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.

Introduction: Patients with pre-existing autoimmune diseases have been excluded from clinical trials of immune checkpoint inhibitors (ICIs) for cancer. Real-world evidence is necessary to understand ICI safety in this population.

Methods: Patients treated with ICIs from 2011 to 2017 were identified using data from a large health insurer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02321-z
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02321-zDOI Listing
March 2019
4 Reads

DNA lesions correlate with lymphocyte function after selective internal radiotherapy.

Cancer Immunol Immunother 2019 Mar 15. Epub 2019 Mar 15.

Institute for Transfusion Medicine, University Hospital Essen, Virchowstraße 179, 45147, Essen, Germany.

In patients with non-resectable hepatic malignancies selective internal radiotherapy (SIRT) with yttrium-90 is an effective therapy. However, previous data indicate that SIRT leads to impaired immune function. The aim of the current study was to determine the extent of DNA lesions in peripheral blood mononuclear cells of SIRT patients and to correlate these lesions with cellular immune responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02323-xDOI Listing

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.

Cancer Immunol Immunother 2019 Mar 12. Epub 2019 Mar 12.

Laura and Issac Perlmutter Cancer Center, New York University School of Medicine, 522 First Avenue, New York, NY, 10016, USA.

Immune-checkpoint inhibition (ICI) treatments improve outcomes for metastatic melanoma; however, > 60% of treated patients do not respond to ICI. Current biomarkers do not reliably explain ICI resistance. Given the link between ICI and autoimmunity, we investigated if genetic susceptibility to autoimmunity modulates ICI efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02318-8DOI Listing
March 2019
2 Reads

HCT-116 colorectal cancer cells secrete chemokines which induce chemoattraction and intracellular calcium mobilization in NK92 cells.

Cancer Immunol Immunother 2019 Mar 7. Epub 2019 Mar 7.

Department of Clinical Sciences, College of Medicine and The Immuno-Oncology Group, Sharjah Institute for Medical Research (SIMR), University of Sharjah, PO Box 27272, Sharjah, United Arab Emirates.

We recently reported that pretreatment of IL-2 activated human natural killer (NK) cells with the drugs dimethyl fumarate (DMF) and monomethyl fumarate (MMF) upregulated the expression of surface chemokine receptor CCR10. Ligands for CCR10, namely CCL27 and CCL28, induced the chemotaxis of these cells. Here, we performed a bioinformatics analysis to see which chemokines might be expressed by the human HCT-116 colorectal cancer cells. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02319-7
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02319-7DOI Listing
March 2019
7 Reads

Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.

Cancer Immunol Immunother 2019 Mar 4. Epub 2019 Mar 4.

Centre Eugène Marquis, rue bataille Flandres Dunkerque, CS44229, 35042, Rennes, France.

Bevacizumab (Bv) remains frequently prescribed in glioblastoma (GBM) patients, especially at recurrence. We conducted a prospective clinical trial with 29 recurrent GBM patients treated with Bv alone with a longitudinal follow-up of different circulating immune cells [complete blood count, myeloid-derived suppressor cells (MDSCs), classical, intermediate, non-classical and Tie2 monocytes, VEGFR1+ and regulatory T cells (Treg)]. We observed a significant increase for leucocytes, neutrophils, eosinophils and classical monocytes and a decrease for the fraction of Treg during the treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02317-9DOI Listing
March 2019
2 Reads

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis.

Cancer Immunol Immunother 2019 May 26;68(5):765-772. Epub 2019 Feb 26.

Department of Dermatology, University Medical Center Tübingen, Liebermeisterstr. 25, 72076, Tübingen, Germany.

Background: Inhibition of the mitogen-activated protein kinase (MAPK) pathway as well as programmed death 1 receptor (PD-1) blockade was shown to prolong overall survival (OS) in patients with advanced B-Raf proto-oncogene (BRAF)-mutant melanoma. However, due to the lack of head-to-head trials, it remains unclear if one of these therapeutic approaches should be preferred in first-line therapy. Here, we present a retrospective analysis comparing anti-PD-1 monotherapy with BRAF/MAPK/ERK kinase (MEK) combined inhibition used as first-line agents in a real-world clinical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02311-1DOI Listing
May 2019
5 Reads

Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model.

Cancer Immunol Immunother 2019 May 26;68(5):753-763. Epub 2019 Feb 26.

Vaccine Development Laboratory, Department of Microbiology, Biomedical Sciences Institute, University of São Paulo, Av. Prof. Lineu Prestes, 1374, São Paulo, SP, 05508-000, Brazil.

The presence of IL-10, produced either by tumor cells or immunosuppressive cells, is frequently associated with a poor prognosis for cancer progression. It may also negatively impact anticancer treatments, such as immunotherapies, that otherwise would promote the activation of cytotoxic T cells capable of detecting and destroying malignant cells. In the present study, we evaluated a new adjuvant approach for anticancer immunotherapy using a plasmid vector encoding a soluble form of the IL-10 receptor (pIL-10R). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-02297-2
Publisher Site
http://dx.doi.org/10.1007/s00262-018-02297-2DOI Listing
May 2019
10 Reads

Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.

Cancer Immunol Immunother 2019 May 21;68(5):743-751. Epub 2019 Feb 21.

Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at University of California, 300 Stein Plaza, Suite 348, Los Angeles, CA, 90095, USA.

Background: Melanoma-associated antigen-A (MAGE-A) and programmed-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We assessed survival outcomes in patients with MAGE-A and PD-L1 expression.

Methods: MAGE-A and PD-L1 expression on neoplastic cells was analyzed using tissue microarrays from patients with UC. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02316-w
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02316-wDOI Listing
May 2019
6 Reads

Natural T cell autoreactivity to melanoma antigens: clonally expanded melanoma-antigen specific CD8 + memory T cells can be detected in healthy humans.

Cancer Immunol Immunother 2019 May 19;68(5):709-720. Epub 2019 Feb 19.

Research and Development Department, Cellular Technology Limited (CTL), 20521 Chagrin Boulevard, Shaker Heights, Cleveland, OH, 44122-5350, USA.

We used four-color ImmunoSpot® assays, in conjunction with peptide pools that cover the sequence of tyrosinase (Tyr), melanoma-associated antigen A3 (MAGE-A3), melanocyte antigen/melanoma antigen recognized by T cells 1 (Melan-A/MART-1), glycoprotein 100 (gp100), and New York esophageal squamous cell carcinoma-1 (NY-ESO-1) to characterize the melanoma antigen (MA)-specific CD8 + cell repertoire in PBMC of 40 healthy human donors (HD). Tyr triggered interferon gamma (IFN-γ)-secreting CD8 + T cells in 25% of HD within 24 h of antigen stimulation ex vivo. MAGE-A3, Melan-A/MART-1, and gp100 also induced recall responses in 10%, 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-02292-7DOI Listing
May 2019
1 Read

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.

Cancer Immunol Immunother 2019 May 15;68(5):799-812. Epub 2019 Feb 15.

CureVac AG, Tübingen, Germany.

CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalation trial, 46 patients with locally advanced (n = 7) or metastatic (n = 39) NSCLC and at least stable disease after first-line treatment received five intradermal CV9201 injections (400-1600 µg of mRNA). The primary objective of the trial was to assess safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02315-xDOI Listing
May 2019
4 Reads

Tumor infiltrating mast cells determine oncogenic HIF-2α-conferred immune evasion in clear cell renal cell carcinoma.

Cancer Immunol Immunother 2019 May 13;68(5):731-741. Epub 2019 Feb 13.

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Purpose: Hypoxia-inducible factor 2α (HIF-2α) overexpression leads to activation of angiogenic pathways. However, little is known about the association between HIF-2α expression and anti-tumor immunity in clear cell renal cell carcinoma (ccRCC). We aimed to explore how HIF-2α influenced the microenvironment and the underlying mechanisms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02314-yDOI Listing
May 2019
4 Reads

Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus.

Cancer Immunol Immunother 2019 May 11;68(5):787-798. Epub 2019 Feb 11.

Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centre, VU University Medical Centre, Vrije University, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

Introduction: Metastatic renal cell cancer (mRCC) patients have a median overall survival (mOS) of approximately 28 months. Until recently, mammalian target of rapamycin (mTOR) inhibition with everolimus was the standard second-line treatment regimen for mRCC patients, improving median progression-free survival (mPFS). Treatment with everolimus supports the expansion of immunosuppressive regulatory T cells (Tregs), which exert a negative effect on antitumor immune responses. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02313-z
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02313-zDOI Listing
May 2019
5 Reads

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.

Cancer Immunol Immunother 2019 May 11;68(5):773-785. Epub 2019 Feb 11.

Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Toronto, Canada.

Adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) has shown significant clinical benefit, but is limited by toxicities due to a requirement for post-infusion interleukin-2 (IL-2), for which high dose is standard. To assess a modified TIL protocol using lower dose IL-2, we performed a single institution phase II protocol in unresectable, metastatic melanoma. The primary endpoint was response rate. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02307-x
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02307-xDOI Listing
May 2019
6 Reads

Imbalances in cellular immunological parameters in blood predetermine tumor onset in a natural mouse model of breast cancer.

Cancer Immunol Immunother 2019 May 11;68(5):721-729. Epub 2019 Feb 11.

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, GSP-7, ul. Miklukho-Maklaya, 16/10, Moscow, 117997, Russia.

The development of new approaches to breast cancer (BC) early diagnosis is an important objective of modern oncology. Although the role of the immune system in cancer initiation process was experimentally well established, the prognostic value of cellular blood immunological parameters (CBIPs) for BC onset prediction was not demonstrated either in clinics or in mouse models. In this study, we focused on revealing informative CBIPs for mammary cancer (MC) onset prediction in the BLRB/BYRB mouse model with a high incidence of natural MC development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02312-0DOI Listing
May 2019
1 Read

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.

Cancer Immunol Immunother 2019 Mar 6;68(3):341-352. Epub 2019 Feb 6.

Lung Cancer Unit, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)-programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02310-2
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02310-2DOI Listing
March 2019
6 Reads

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma.

Cancer Immunol Immunother 2019 Apr 6;68(4):619-629. Epub 2019 Feb 6.

Comprehensive Cancer Center, The Ohio State University, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, N924 Doan Hall 410 W. 10th Ave, Columbus, OH, 43210-1228, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02308-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447692PMC
April 2019
2 Reads

Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.

Cancer Immunol Immunother 2019 Apr 6;68(4):587-598. Epub 2019 Feb 6.

Department of Medical Biotechnology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1 Street, 80-211, Gdańsk, Poland.

Anti-CD20 monoclonal antibodies (mAbs) rituximab and ofatumumab are potent activators of the classical complement pathway, and have been approved for the treatment of B-cell malignancies. However, complement exhaustion and overexpression of complement inhibitors by cancer cells diminish their therapeutic potential. The strategies of targeting membrane complement inhibitors by function-blocking antibodies and the supplementation with fresh frozen plasma have been proposed to overcome tumour cell resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02304-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447516PMC
April 2019
3.941 Impact Factor

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

Cancer Immunol Immunother 2019 Apr 5;68(4):609-618. Epub 2019 Feb 5.

Merck KGaA, Darmstadt, Germany.

Background: Response rates are primary endpoints in many oncology trials; however, correlation with overall survival (OS) is not uniform across cancer types, treatments, or lines of therapy. This study explored the association between objective response (OR) and OS in patients with chemotherapy-refractory metastatic Merkel cell carcinoma who received avelumab (anti-PD-L1).

Methods: Eighty-eight patients enrolled in JAVELIN Merkel 200 (part A; NCT02155647) received i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-02295-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447510PMC
April 2019
5 Reads

Correction to: CD73 expression in normal and pathological human hepatobiliopancreatic tissues.

Cancer Immunol Immunother 2019 Mar;68(3):529

Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, rue du Bugnon 25, 1011, Lausanne, Switzerland.

The following information must be added to the published article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02309-9DOI Listing
March 2019
5 Reads

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Cancer Immunol Immunother 2019 Apr 28;68(4):599-608. Epub 2019 Jan 28.

Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA.

Background: Checkpoint inhibitors have recently been approved for the treatment of patients with hepatocellular carcinoma (HCC). However, biomarkers, which will help identify patients responding to therapy, are missing. We recently tested the combination of anti-CTLA4 treatment (tremelimumab) with loco-regional therapy in patients with HCC and reported a partial response rate of 26%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02299-8DOI Listing
April 2019
2 Reads

Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates.

Cancer Immunol Immunother 2019 Apr 25;68(4):687-697. Epub 2019 Jan 25.

Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 28, 6500 HB, Nijmegen, The Netherlands.

In cancer, infection and inflammation, the immune system's function can be dysregulated. Instead of fighting disease, immune cells may increase pathology and suppress host-protective immune responses. Myeloid cells show high plasticity and adapt to changing conditions and pathological challenges. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02302-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447515PMC
April 2019
3 Reads

A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients.

Cancer Immunol Immunother 2019 Apr 23;68(4):577-585. Epub 2019 Jan 23.

Department of Anatomical Pathology, Hiroshima University Hospital, 2-3, 1-Chome Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.

Tumor-infiltrating lymphocytes are an important prognostic factor after neoadjuvant chemotherapy (NAC) in patients with breast cancer. Natural killer (NK) cells play critical roles in antitumor immune surveillance. Here, we assessed the relationship between peripheral natural killer (pNK) cell activity, tumor microenvironmental factors (TMEFs), and the therapeutic efficacy of preoperative chemotherapy in patients with breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02305-zDOI Listing
April 2019
3 Reads

Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe?

Cancer Immunol Immunother 2019 Apr 22;68(4):563-575. Epub 2019 Jan 22.

Department of General-, Visceral-, Transplant-, Vascular- and Paediatric Surgery, University Hospital of Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.

The prognostic value of the local immune phenotype in patients with colorectal cancer has been extensively studied. Neoadjuvant radiotherapy and/or chemotherapy may potentially influence these immune responses. In this study, we examined the prognostic role of indoleamine-2,3-Dioxygenase (IDO1) and infiltrating cytotoxic T lymphocytes (CD8+) in locally advanced rectal carcinomas after neoadjuvant treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02306-yDOI Listing
April 2019
2 Reads

Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.

Cancer Immunol Immunother 2019 Apr 21;68(4):553-561. Epub 2019 Jan 21.

Department of Gastroenterology, Hepatology and Nutrition, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA.

Background: Gastrointestinal (GI) immune-related adverse events (irAEs) commonly limit immune checkpoint inhibitors' (ICIs) treatment, which is very effective for metastatic melanoma. The independent impact of GI-irAEs on patients' survival is not well studied. We aimed to assess the impact of GI-irAEs on survival rates of patients with metastatic melanoma using multivariate model. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02303-1
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02303-1DOI Listing
April 2019
9 Reads
3.941 Impact Factor

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.

Cancer Immunol Immunother 2019 Apr 19;68(4):545-551. Epub 2019 Jan 19.

Hôpital Saint André, service de Dermatologie, University Hospital of Bordeaux, 1 rue Jean Burguet, 33000, Bordeaux, France.

Background: Checkpoint inhibitors are first-line therapies in melanoma, but safety in older adults has not yet been assessed. Ipilimumab improves survival, but immunologic-related adverse events (AEs) can be threatening, and its use in elderly people raises questions.

Aim: To assess safety in a cohort of very elderly patients treated with ipilimumab. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02298-9
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02298-9DOI Listing
April 2019
7 Reads

Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.

Cancer Immunol Immunother 2019 Apr 17;68(4):533-544. Epub 2019 Jan 17.

Invectys, Pépinière Paris Santé Cochin, 27, rue du Faubourg Saint Jacques, 75014, Paris, France.

Cancer immunotherapy is seeing an increasing focus on vaccination with tumor-associated antigens (TAAs). Human telomerase (hTERT) is a TAA expressed by most tumors to overcome telomere shortening. Tolerance to hTERT can be easily broken both naturally and experimentally and hTERT DNA vaccine candidates have been introduced in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2272-3DOI Listing
April 2019
4 Reads

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial.

Cancer Immunol Immunother 2019 Mar 17;68(3):503-515. Epub 2019 Jan 17.

Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

For the treatment of metastatic renal cell cancer several strategies are used among which the mTOR inhibitor everolimus. As mTOR plays an important role in the immune system, e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2288-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426984PMC
March 2019
2 Reads

STAT3 inhibition specifically in human monocytes and macrophages by CD163-targeted corosolic acid-containing liposomes.

Cancer Immunol Immunother 2019 Mar 14;68(3):489-502. Epub 2019 Jan 14.

Department of Clinical Biochemistry, Aarhus University Hospital, Palle Juul-Jensen Boulevard 99, 8200, Aarhus N, Denmark.

Tumor-associated macrophages (TAMs) are of major importance in cancer-related immune suppression, and tumor infiltration by CD163 TAMs is associated with poor outcome in most human cancers. Therefore, therapeutic strategies for reprogramming TAMs from a tumor-supporting (M2-like) phenotype towards a tumoricidal (M1-like) phenotype are of great interest. Activation of the transcription factor STAT3 within the tumor microenvironment is associated with worse prognosis, and STAT3 activation promotes the immunosuppressive phenotype of TAMs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02301-3
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02301-3DOI Listing
March 2019
10 Reads

Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.

Cancer Immunol Immunother 2019 Mar 11;68(3):479-488. Epub 2019 Jan 11.

Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.

T cell responses are crucial for anti-tumor immunity. In chronic viral infections, anti-tumor T cell responses can be compromised due to various immunological mechanisms, including T cell exhaustion. To study mechanisms of anti-tumor immunity during a chronic viral infection, we made use of the well-established Friend virus (FV) mouse model. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-019-02300-4
Publisher Site
http://dx.doi.org/10.1007/s00262-019-02300-4DOI Listing
March 2019
10 Reads

CD73 expression in normal and pathological human hepatobiliopancreatic tissues.

Cancer Immunol Immunother 2019 Mar 4;68(3):467-478. Epub 2019 Jan 4.

Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, rue du Bugnon 25, 1011, Lausanne, Switzerland.

Background: The tumor-expressed CD73 ectonucleotidase generates immune tolerance and promotes invasiveness via adenosine production from degradation of AMP. While anti-CD73 blockade treatment is a promising tool in cancer immunotherapy, a characterization of CD73 expression in human hepatobiliopancreatic system is lacking.

Patients And Methods: CD73 expression was investigated by immunohistochemistry in a variety of non-neoplastic and neoplastic conditions of the liver, pancreas, and biliary tract. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-2290-1
Publisher Site
http://dx.doi.org/10.1007/s00262-018-2290-1DOI Listing
March 2019
24 Reads

Schwann cells shape the neuro-immune environs and control cancer progression.

Cancer Immunol Immunother 2019 Jan 3. Epub 2019 Jan 3.

Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

At present, significant experimental and clinical data confirm the active involvement of the peripheral nervous system (PNS) in different phases of cancer development and progression. Most of the research effort focuses on the impact of distinct neuronal types, e.g. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-02296-3
Publisher Site
http://dx.doi.org/10.1007/s00262-018-02296-3DOI Listing
January 2019
13 Reads

Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.

Cancer Immunol Immunother 2019 Mar 2;68(3):443-454. Epub 2019 Jan 2.

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.

Adenocarcinoma of the ampulla of Vater (AOV) is classified into intestinal type (IT) and pancreatobiliary type (PB); however, the immunological properties of these subtypes remain to be characterized. Here, we evaluated the clinical implications of PD-L1 expression and CD8 T lymphocyte density in adenocarcinomas of the AOV and their potential association with Yes-associated protein (YAP). We analyzed 123 adenocarcinoma-of-the-AOV patients who underwent surgical resection, and tumors were classified into IT or PB type. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-02293-6DOI Listing
March 2019
4 Reads

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice.

Cancer Immunol Immunother 2019 Mar 2;68(3):455-466. Epub 2019 Jan 2.

Cancer Immunology, Inflammation and Tolerance Program, Georgia Cancer Center, Augusta University, 1410 Laney Walker Blvd., CN-4142, Augusta, GA, 30912, USA.

Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL) epitopes have long been considered as a simple and cost-effective approach to treat cancer. However, the efficacy of these vaccines in the clinic in patients with measurable disease remains questionable. We believe that the poor performance of peptide vaccines is due to their inability to generate sufficiently large CTL responses that are required to have a positive impact against established tumors. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00262-018-02294-5
Publisher Site
http://dx.doi.org/10.1007/s00262-018-02294-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428613PMC
March 2019
2 Reads

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Cancer Immunol Immunother 2019 Mar 27;68(3):517-527. Epub 2018 Dec 27.

Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, 12902, Magnolia Drive, FOB1, Tampa, FL, 33612, USA.

Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected with wild-type TP53 (vaccine) were administered to patients with extensive-stage small cell lung cancer after chemotherapy. Patients were randomized 1:1:1 to arm A (observation), arm B (vaccine alone), or arm C (vaccine plus all-trans-retinoic acid). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-018-2287-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426813PMC
March 2019
1 Read